Intuitive Surgical (ISRG) Stock
Leader in robotic surgery with high margin recurring revenue. Here's the price, business snapshot, and what's worth knowing about Intuitive Surgical in August 2026.
Intuitive Surgical (ISRG) is the dominant name in robotic-assisted surgery, best known for its da Vinci surgical systems that enable minimally invasive procedures. With a sizeable installed base and recurring revenue from instruments, accessories and service contracts, the company has built a high-margin business that benefits as hospitals upgrade systems and expand robotic programmes. Key growth drivers include wider clinical adoption across specialties, new product introductions and expansion into less invasive procedures. Investors should weigh these opportunities against concentration risks — substantial reliance on a single product family, ongoing R&D spending, regulatory and reimbursement dynamics, and sensitivity to hospital capital budgets. Competition from established medical groups and new robotics entrants is rising. The market cap (~$165.9bn) reflects premium expectations of persistent growth and margin expansion; such expectations can reverse. This overview is educational and not investment advice — consider your risk tolerance and seek personalised guidance before acting.
Why It’s Moving
ISRG is drawing fresh analyst support after a strong quarter, even as growth worries keep the rally in check.
- Analysts turned more constructive after Intuitive Surgical’s latest quarter topped expectations, reinforcing confidence that demand for its robotic systems is still growing even as the stock has lagged the broader market.
- The bullish case has been supported by a fresh upgrade from Oppenheimer and a still-positive consensus view across Wall Street, signaling that many analysts see the recent pullback as overdone relative to the company’s operating momentum.
- Offsetting the upbeat earnings tone, some investors remain cautious after a downgrade from Wall Street Zen and continued talk of slower U.S. procedure growth, which has kept sentiment mixed despite the strong results.
ISRG is drawing fresh analyst support after a strong quarter, even as growth worries keep the rally in check.
- Analysts turned more constructive after Intuitive Surgical’s latest quarter topped expectations, reinforcing confidence that demand for its robotic systems is still growing even as the stock has lagged the broader market.
- The bullish case has been supported by a fresh upgrade from Oppenheimer and a still-positive consensus view across Wall Street, signaling that many analysts see the recent pullback as overdone relative to the company’s operating momentum.
- Offsetting the upbeat earnings tone, some investors remain cautious after a downgrade from Wall Street Zen and continued talk of slower U.S. procedure growth, which has kept sentiment mixed despite the strong results.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for ISRG is expected on October 20, 2026, based on its historical reporting pattern. This release should cover Q3 2026 results. For an investor briefing, that date is the current estimated earnings window unless the company announces a confirmed schedule sooner.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intuitive Surgical's stock with a target price of $548.39, indicating growth potential.
Financial Health
Intuitive Surgical is performing well with strong revenue, cash flow, and profit margins.
Dividend
Intuitive Surgical does not pay a dividend, which can be due to reinvesting profits for growth. If you invested $1000, you would receive $0 a year in dividends.
Why You’ll Want to Watch This Stock
Recurring revenue model
Consumables and service contracts create predictable follow-on sales, though hospital budgets and procedure volumes can affect revenue.
Innovation and R&D
Regular product updates and new platforms can open markets, but they require heavy R&D and face regulatory hurdles.
Global adoption trends
Growing use of minimally invasive surgery offers a large addressable market, yet adoption and reimbursement vary by region.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
